CHF Solutions Signs International Distribution and Services Agreement with Singapore-based TRANSMEDIC Pte Ltd.
December 13 2017 - 08:00AM
CHF Solutions, Inc. (NASDAQ:CHFS) announced today that it has
entered into an international distribution agreement with
Singapore-based TRANSMEDIC Pte Ltd to market and support CHF
Solutions’ Aquadex FlexFlow® System in the region.
“We are very pleased to expand our market reach into Singapore
with our new distributor partner, TRANSMEDIC Pte Ltd, a premier
medical technology sales and distribution company serving
hospitals, clinics and health-centers in Southeast Asia,” said John
Erb, CEO of CHF Solutions. “TRANSMEDIC has the market reach and
service breadth to meet our expansion goals as we continue to
execute our US and international growth plans. We have been in
contact with healthcare providers that already own Aquadex FlexFlow
consoles, and we look forward to TRANSMEDIC being able to service
those units, bring them back into use and expanding the usage in
the area,” Mr. Erb concluded.
About TRANSMEDIC Pte Ltd.
Formed in 1980, TRANSMEDIC offers direct sales, education and
training plus technical support and maintenance for numerous
medical technology, supplying hospitals, clinics and health-centers
with a range of high quality products from 40 different companies,
incorporating the latest technological advances. From its head
office in Singapore and 7 offices allover Southeast Asia, this
organization of 400 people provide full coverage of the SouthEast
region. TRANSMEDIC is committed to provide the medical profession
with a range of quality products incorporating the latest
technology and backed by the highest level of customer service and
support.
About CHF Solutions
CHF Solutions, Inc. (NASDAQ:CHFS) is a medical device company
focused on commercializing the Aquadex FlexFlow system for
Aquapheresis® therapy. The Aquadex FlexFlow system, is indicated
for temporary (up to eight hours) ultrafiltration treatment of
patients with fluid overload who have failed diuretic therapy, and
extended (longer than 8 hours) ultrafiltration treatment of
patients with fluid overload who have failed diuretic therapy and
require hospitalization. All treatments must be administered by a
healthcare provider, under physician prescription, both of whom
having received training in extracorporeal therapies. The
company's mission is to predict, measure, and control patient
fluid balance through science, collaboration, and innovative
medical technology. CHF Solutions is a Delaware corporation
headquartered in Minneapolis with wholly owned subsidiaries in
Australia and Ireland. The company has been listed on the NASDAQ
Capital Market since February 2012.
Forward-Looking Statements
Certain statements in this release are forward-looking
statements within the meaning of the Private Securities Litigation
Reform Act of 1995, including without limitation, statements
regarding meeting our international expansion goals and TRANSMEDIC
being able to servicing existing Aquadex FlexFlow consoles,
bringing them back into use and expand the usage of Aquadex
FlexFlow consoles. Forward-looking statements are
predictions, projections and other statements about future events
that are based on current expectations and assumptions and, as a
result, are subject to risks and uncertainties. Many factors could
cause actual future events to differ materially from the
forward-looking statements in this release, including, without
limitation, those risk associated with our ability to execute on
our recently announced strategic realignment, the possibility that
we may be unable to raise sufficient funds necessary for our
anticipated operations, our post-market clinical data collection
activities, benefits of our products to patients, our expectations
with respect to product development and commercialization efforts,
our ability to increase market and physician acceptance of our
products, potentially competitive product offerings, intellectual
property protection, our ability to integrate acquired businesses,
our expectations regarding anticipated synergies with and benefits
from acquired businesses, and other risks and uncertainties
described in our filings with the SEC. Forward-looking statements
speak only as of the date when made. CHF Solutions does not assume
any obligation to publicly update or revise any forward-looking
statements, whether as a result of new information, future events
or otherwise.
For further information, please contact:
Claudia Napal DraytonChief Financial OfficerCHF Solutions
Inc. T: +1-952-345-4205
Investor Relations:CHF Solutions, Inc.ir@chf-solutions.com
-or-
Bret ShapiroManaging PartnerCORE IR516 222
2560brets@coreir.comwww.coreir.com
CHF Solutions (NASDAQ:CHFS)
Historical Stock Chart
From Feb 2024 to Mar 2024
CHF Solutions (NASDAQ:CHFS)
Historical Stock Chart
From Mar 2023 to Mar 2024